Suppr超能文献

使用昔康类药物治疗的骨关节炎患者的血液谷胱甘肽过氧化物酶活性

Blood Glutathione Peroxidase Activity in Patients with Osteoarthritis Treated with Oxicams.

作者信息

Amzoiu D C, Pisoschi C G, Stoian Bulearcă A M, Rău G

机构信息

University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, Department of Pharmaceutical Chemistry.

University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, Department of Biochemistry.

出版信息

Curr Health Sci J. 2016 Jan-Mar;42(1):29-34. doi: 10.12865/CHSJ.42.01.04. Epub 2016 Mar 29.

Abstract

PURPOSE

The main objective of this study was the comparison of the influence for three non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the oxicam class, namely piroxicam and tenoxicam, as non-selective inhibitors of cyclooxygenase (COX), and meloxicam, a selective COX-2 inhibitor, on glutathione peroxidase (GPx) activity in patients with osteoarthritis of the knee.

MATERIAL/METHODS: Thirty adult subjects clinically and radiographically diagnosed with knee osteoarthritis, who were not previously subjected to any treatment, were enrolled. They were divided in three groups, each with ten subjects. The serum levels of GPx were assessed at baseline and after twenty days of treatment. The first group received piroxicam at a dose of 20 mg orally daily, the second group was treated with tenoxicam at a dose of 20 mg orally daily, and in the third group meloxicam was administrated in a dose of 15 mg orally daily.

RESULTS

After the treatment, it was observed an increase of the GPx activity in all groups. The group treated with meloxicam presented the highest rise in the GPx level (p = 0.052).

CONCLUSIONS

The 20 days study concerning the effects of treatment with NSAIDs belonging to the oxicam class in subjects with knee osteoarthritis revealed that piroxicam, tenoxicam and meloxicam determined a slightly increase in the GPx activity, although this rise had no statistical significance.

摘要

目的

本研究的主要目的是比较三种属于昔康类的非甾体抗炎药(NSAIDs),即作为环氧化酶(COX)非选择性抑制剂的吡罗昔康和替诺昔康,以及选择性COX-2抑制剂美洛昔康,对膝骨关节炎患者谷胱甘肽过氧化物酶(GPx)活性的影响。

材料/方法:纳入30名临床和影像学诊断为膝骨关节炎且此前未接受过任何治疗的成年受试者。他们被分为三组,每组10名受试者。在基线和治疗20天后评估GPx的血清水平。第一组每天口服20mg吡罗昔康,第二组每天口服20mg替诺昔康,第三组每天口服15mg美洛昔康。

结果

治疗后,观察到所有组的GPx活性均增加。美洛昔康治疗组的GPx水平升高最为明显(p = 0.052)。

结论

关于昔康类NSAIDs对膝骨关节炎患者治疗效果的20天研究表明,吡罗昔康、替诺昔康和美洛昔康使GPx活性略有增加,尽管这种增加无统计学意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b7/6256138/974bc8932684/CHSJ-42-01-04-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验